California Public Employees Retirement System Has $6.55 Million Position in Exact Sciences Corporation (EXAS)

California Public Employees Retirement System increased its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 5.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 185,100 shares of the medical research company’s stock after acquiring an additional 10,300 shares during the quarter. California Public Employees Retirement System owned approximately 0.16% of Exact Sciences Corporation worth $6,547,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State of Wisconsin Investment Board purchased a new position in Exact Sciences Corporation during the second quarter worth approximately $3,006,000. Victory Capital Management Inc. purchased a new position in Exact Sciences Corporation during the second quarter worth approximately $29,450,000. Eagle Asset Management Inc. raised its stake in Exact Sciences Corporation by 19.6% during the second quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock worth $65,688,000 after purchasing an additional 304,598 shares during the period. Federated Investors Inc. PA raised its stake in Exact Sciences Corporation by 53.3% during the second quarter. Federated Investors Inc. PA now owns 34,553 shares of the medical research company’s stock worth $1,222,000 after purchasing an additional 12,018 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Exact Sciences Corporation during the first quarter worth approximately $8,298,000. Hedge funds and other institutional investors own 85.22% of the company’s stock.

EXAS has been the topic of a number of recent analyst reports. BidaskClub raised shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Leerink Swann set a $45.00 target price on shares of Exact Sciences Corporation and gave the company a “buy” rating in a research note on Thursday, August 24th. Robert W. Baird reissued a “buy” rating and issued a $49.00 target price on shares of Exact Sciences Corporation in a research note on Friday, October 6th. Zacks Investment Research raised shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a research note on Tuesday, September 26th. Finally, Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 target price on the stock. in a research note on Thursday, July 6th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Exact Sciences Corporation presently has a consensus rating of “Buy” and an average target price of $43.71.

WARNING: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/10/15/california-public-employees-retirement-system-has-6-55-million-position-in-exact-sciences-corporation-exas.html.

In related news, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the transaction, the senior vice president now directly owns 64,991 shares in the company, valued at approximately $3,064,975.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Thomas D. Carey bought 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were bought at an average price of $37.71 per share, with a total value of $94,275.00. Following the completion of the purchase, the director now owns 60,858 shares in the company, valued at $2,294,955.18. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 237,444 shares of company stock valued at $10,412,421. Corporate insiders own 4.00% of the company’s stock.

Shares of Exact Sciences Corporation (NASDAQ EXAS) opened at 47.41 on Friday. The stock’s market cap is $5.65 billion. The company’s 50-day moving average is $44.75 and its 200 day moving average is $36.21. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $50.65.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.10. The business had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities research analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current year.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply